(Q54480001)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

0 references

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Per Näsman

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Hareth Nahi

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Johan Liwing

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Katarina Uttervall

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Johan Lund

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Anders Aldrin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Cecilie Blimark

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Kristina Carlson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Jon Enestig

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Max Flogegård

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Karin Forsberg

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Astrid Gruber

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Helene Haglöf Kviele

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Peter Johansson

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Birgitta Lauri

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Ulf-Henrik Mellqvist

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Agneta Swedin

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Magnus Svensson

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Gösta Gahrton

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Johan Aschan

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

language of work or name

English

0 references

publication date

9 December 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Haematology

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

164

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

684-693

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

2 March 2020

cites work

1 reference

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

21 January 2018

1 reference

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.

21 January 2018

1 reference

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

21 January 2018

1 reference

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

21 January 2018

1 reference

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

21 January 2018

1 reference

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

21 January 2018

1 reference

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

21 January 2018

1 reference

Clinical course of patients with relapsed multiple myeloma

21 January 2018

1 reference

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective

21 January 2018

1 reference

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

21 January 2018

1 reference

Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978.

21 January 2018

1 reference

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

21 January 2018

1 reference

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

21 January 2018

1 reference

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.

21 January 2018

1 reference

A combination regimen of bortezomib, cyclophosphamide and betamethasone gives quicker, better and more durable response than VAD/CyBet regimens: results from a Swedish retrospective analysis.

21 January 2018

1 reference

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

21 January 2018

1 reference

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.12685

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24313224%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference